Avacincaptad pegol

• UNSPSC Description:

  Avacincaptad pegol, which is a pegylated aptamer, has garnered significant attention as a C5 complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA)[1][2].

• Target Antigen:

  Complement System

• Type:

  Oligonucleotides

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/avacincaptad-pegol.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [Avacincaptad pegol]

• Molecular Weight:

  52603 (Approximately)

• References & Citations:

  [1]Rehan M Hussain, et al. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059.|[2]Glenn J Jaffe, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  1613641-69-2